Advertisement
Canada markets close in 6 hours 15 minutes

  • S&P/TSX

    21,801.08
    +92.64 (+0.43%)
     

  • S&P 500

    5,014.61
    +3.49 (+0.07%)
     

  • DOW

    37,932.35
    +156.97 (+0.42%)
     

  • CAD/USD

    0.7276
    +0.0012 (+0.17%)
     

  • CRUDE OIL

    82.98
    +0.25 (+0.30%)
     

  • Bitcoin CAD

    89,160.62
    +3,286.12 (+3.83%)
     

  • CMC Crypto 200

    1,330.02
    +17.40 (+1.33%)
     

  • GOLD FUTURES

    2,399.10
    +1.10 (+0.05%)
     

  • RUSSELL 2000

    1,934.39
    -8.57 (-0.44%)
     

  • 10-Yr Bond

    4.6020
    -0.0450 (-0.97%)
     

  • NASDAQ

    15,558.95
    -42.55 (-0.27%)
     

  • VOLATILITY

    18.65
    +0.65 (+3.61%)
     

  • FTSE

    7,834.25
    -42.80 (-0.54%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6814
    -0.0007 (-0.10%)
     
MARKETS LIVE BLOG:

STOCKS OPEN MIXED AFTER ISRAEL STRIKE-FUELLED TUMBLE

Shares of Netflix, the first of the megacap techs to report, slide in early trading

New Strong Sell Stocks for November 18th

Zacks Equity Research
·1 min read

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Amyris, Inc. AMRS is a biotechnology company. The Zacks Consensus Estimate for its current year earnings has been revised 29.3% downward over the last 30 days.

ThermoGenesis Holdings, Inc. THMO is a developer and marketer of automated technologies for chimeric antigen receptor (CAR)-T and other cell-based therapies. The Zacks Consensus Estimate for its current year earnings has been revised 42.4% downward over the last 30 days.

Cogent Biosciences, Inc. COGT is engaged in developing a pipeline of novel therapies to treat cancer patients. The Zacks Consensus Estimate for its current year earnings has been revised more than 100% downward over the last 30 days.

ADVERTISEMENT

Dolby Laboratories, Inc. DLB is a creator of audio and imaging technologies. The Zacks Consensus Estimate for its current year earnings has been revised 1.6% downward over the last 30 days.

HOOKIPA Pharma Inc. HOOK is a clinical stage biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 16.1% downward over the last 30 days.

View the entire Zacks Rank #5 List.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Dolby Laboratories (DLB) : Free Stock Analysis Report
 
HOOKIPA Pharma Inc. (HOOK) : Free Stock Analysis Report
 
Amyris, Inc. (AMRS) : Free Stock Analysis Report
 
Cogent Biosciences, Inc. (COGT) : Free Stock Analysis Report
 
Cesca Therapeutics Inc. (THMO) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research